Navigation Links
LX4211 for Diabetes Shown to Reduce Fasting and Post-Prandial Blood Sugar in Healthy Subjects
Date:9/13/2011

THE WOODLANDS, Texas, Sept. 13, 2011 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, reported positive data from a recently completed clinical trial and mechanistic study of LX4211, a dual inhibitor of the sodium glucose transporters 1 and 2 (SGLT1 and SGLT2).  The favorable safety profile and effects on multiple parameters of glycemic control and cardiovascular health in healthy normal subjects support the broad potential of LX4211 in the treatment of diabetes and associated metabolic conditions.

"Newly observed in this study were the effects of LX4211, in healthy volunteers, of decreasing postprandial glucose levels without hypoglycemia and substantially reducing triglycerides," said Brian Zambrowicz, Ph.D., executive vice president and chief scientific officer.  "Notably, the magnitudes of the reductions in triglycerides were similar to current standard of care prescription and clinical-stage medicines. By contrast, reported results of SGLT2-selective compounds have demonstrated minimal or no reductions in postprandial glucose in healthy subjects and minimal or no triglyceride decreases in either healthy normal volunteers or patients with type 2 diabetes."

Results from the study demonstrated that the 400 mg solid oral dose of LX4211 compared to placebo significantly reduced mean changes from baseline in fasting plasma glucose (p=0.005) and post-prandial glucose levels (p<0.001) in parallel with meaningful mean increases from baseline in total and active GLP-1 (p=0.055 and p=0.003, respectively) as well as PYY (p<0.001).  GLP-1 is associated with improved glucose control and decreased food intake through reduction of appetite.  PYY is a gas
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes
2. Phase 2 Trial of LX4211 Demonstrates Significant and Rapid Improvements in Multiple Parameters in Type 2 Diabetic Patients
3. Lexicon Presents Data Describing LX4211 Positive Phase 2 Clinical Results and Novel Mechanism of Action for Type 2 Diabetes
4. Lexicon Announces Positive Results from New Clinical Study of LX4211 in Type 2 Diabetes Patients
5. Lexicon Presents LX4211 Mechanism of Action Data at American Diabetes Association Meeting and Announces Commencement of Phase 2b Clinical Trial in Type 2 Diabetes
6. Lexicon Presents LX4211 Clinical Data at European Association for the Study of Diabetes Annual Meeting
7. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
8. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
9. The Heart, Diabetes, And Weight Loss Centers of New York Introduce the New Science of Metabolic Diagnosis and Weight Management
10. Isis Initiates Phase 1 Study of ISIS 325568 Targeting Glucagon Receptor to Treat Type 2 Diabetes
11. Diabetes Research Institute Invention Promotes Growth of Stem Cells into Insulin-Producing Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... , Aug. 22, 2014  Cannabis Science, Inc. ... formulation-based drug development and related consulting, is pleased ... international medical cannabis conference taking place at the ... , on October 22, 2014.  The multilingual ... such as researchers, health professionals, and patients, to ...
(Date:8/22/2014)...  WaferGen Bio-systems, Inc. (NASDAQ: WGBS) today announced the ... common stock and warrants at a price of $10,000 ... to deducting underwriting discounts and commissions and offering expenses ... immediately separable and will be issued separately.  The shares ... The NASDAQ Stock Market under the ticker symbol "WGBS" ...
(Date:8/21/2014)... Aug. 21, 2014  Vermillion, Inc. (NASDAQ: ... cancers and women,s health, has appointed Holly B. ... Markets. Ms. Bauzon has a proven track ... coverage for laboratory services companies. She has more than ... Inc., where she held the position of Director, Lab ...
Breaking Medicine Technology:Cannabis Science, Inc. (CBIS) to Sponsor 3rd International Conference on Cannabinoids in Medicine in October 2014 in Strasbourg, France 2Cannabis Science, Inc. (CBIS) to Sponsor 3rd International Conference on Cannabinoids in Medicine in October 2014 in Strasbourg, France 3WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 2WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 3WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 4Vermillion Appoints Holly B. Bauzon as VP of Sales and Managed Markets 2
... from a Phase 1/2 study of perifosine in combination ... from or refractory to bortezomib , ... Biopharmaceuticals, Inc. (Nasdaq: KERX ) today announced ... combination with bortezomib (+/- dexamethasone) in patients with relapsed/refractory ...
... SOUTH SAN FRANCISCO, Calif., Dec. 9 Portola,Pharmaceuticals, ... advances in cardiovascular disease, inflammatory disease,and cancer, today ... a large Phase II clinical trial of PRT060128, ... undergoing non-urgent,percutaneous coronary intervention (PCI). , ...
Cached Medicine Technology:Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology 2Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology 3Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology 4Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology 5Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology 6Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology 7Portola Pharmaceuticals Initiates Phase II Trial of Novel IV and Oral Anti-Platelet Drug in Non-Urgent Percutaneous Coronary Intervention 2Portola Pharmaceuticals Initiates Phase II Trial of Novel IV and Oral Anti-Platelet Drug in Non-Urgent Percutaneous Coronary Intervention 3
(Date:8/22/2014)... stenting to open blockages in the kidney arteries ... from modern clinical trials, according to new recommendations ... and Cardiovascular Interventions today by the Society ... Hospitals Case Medical Center,s Sahil Parikh, MD, Director, ... Case Western Reserve University School of Medicine was ...
(Date:8/22/2014)... 2014 (HealthDay News) -- Counseling may do little to ... finds. Researchers analyzed 66 studies that included nearly ... at high risk for drinking problems. Participants in 49 ... in the rest of the studies attended group sessions ... A counseling technique called motivational interviewing was used in ...
(Date:8/22/2014)... A new, online conference is coming August 25th-29th, 2014 about ... open to everyone. Over 20 top experts will be ... how to stop emotional eating, start eating healthier and successful ... not a diet. The concept is about how to make ... don't eat that" approach. , You can sign up for ...
(Date:8/22/2014)... 22, 2014 Key West Health & ... revealed their much anticipated study results of the 12 ... and released an accompanying infographic on their website. It ... have a major impact on the skin and contribute ... more. , When asked how they determined the results, ...
(Date:8/22/2014)... Medical Oncology (ESMO), the leading pan-European organisation representing ... three outstanding individuals receiving the Society,s esteemed annual ... Bokemeyer, Heikki Joensuu and Peter Boyle on the ... Madrid, Spain. , Carsten Bokemeyer will receive the ... transition of cancer discovery into real benefit at ...
Breaking Medicine News(10 mins):Health News:UH Case Medical Center's Dr. Parikh authors SCAI paper on renal artery stenosis treatment 2Health News:UH Case Medical Center's Dr. Parikh authors SCAI paper on renal artery stenosis treatment 3Health News:Counseling Does Little to Deter Youth Drinking, Review Finds 2Health News:20 Top Experts Discuss How to Unravel the Food-Mood Connection 2Health News:Key West Health & Beauty Announces The 12 Best & Worst U.S. Cities For Skin Study 2Health News:ESMO honors outstanding oncology professionals 2Health News:ESMO honors outstanding oncology professionals 3
... , FRIDAY, April 27 (HealthDay News) -- Two genetic ... as primary open-angle glaucoma, according to new research. Glaucoma ... U.S. National Eye Institute said in a news release. ... worldwide, is due to irreversible damage to the optic nerve," ...
... the structure of a key part of the human obesity ... which could help provide new treatments for the complications of ... in the journal Structure , will greatly enhance the ... the receptor for the obesity hormone leptin. This could have ...
... , FRIDAY, April 27 (HealthDay News) -- Children who are bullied ... time they are 12 years old, according to a new study. ... the United Kingdom said its findings, published online April 27 in ... for this type of behavior. Examples of self-harming behaviors ...
... 5th Annual Jean Sindab Triple Negative Breast Cancer ... Emory University, provides an intimate learning environment in ... cancers (TNBC) will be explored. Nationally recognized speakers ... on current research in TNBC. TNBC affects young ...
... the discovery of small molecules that kill cancer cells ... results, in both cell and mouse models, demonstrate that ... by viral proteins, thus killing the infected tumor cells. ... April 20 issue of the journal Chemistry & ...
... ATLANTA April 26, 2012 New guidelines from ... a healthy weight, getting adequate physical activity, and eating ... and increase the likelihood of disease-free survival after a ... and Physical Activity Guidelines for Cancer Survivors, published early ...
Cached Medicine News:Health News:Research Gets Closer to Genetic Roots of Glaucoma 2Health News:New drug to tackle fat problems 2Health News:Bullied Children at Greater Risk for Self-Harm, Study Finds 2Health News:Small molecular bodyguards kill HPV-infected cancer cells by protecting tumor-suppressor 2Health News:Small molecular bodyguards kill HPV-infected cancer cells by protecting tumor-suppressor 3Health News:Guidelines say diet, exercise, weight control improve odds after cancer diagnosis 2Health News:Guidelines say diet, exercise, weight control improve odds after cancer diagnosis 3
... patient, it's important to rule out ... with a test that gives the ... hCG levels. Beckman Coulters ICON II ... determination of hCG in serum or ...
AUTION ELEVEN is the eleventh model of AUTION series which is ideal for use in small-to-medium-sized hospitals and clinics with its smart design and features....
Drugs of Abuse (DoA) Array is used for in-vitro diagnostic tests for the qualitative determination of the parent molecule and metabolites of drugs in human urine....
Drugs of Abuse (DoA) Array is used for in-vitro diagnostic tests for the qualitative determination of the parent molecule and metabolites of drugs in human urine....
Medicine Products: